NRD
CRMD icon

Nebula Research & Development’s CorMedix CRMD Stock Holding History

Nebula Research & Development’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,475
Closed -$57.4K – 525
2023
Q2 		$57.4K Buy
+14,475
New +$71.6K 0.04% 312

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nebula Research & Development's CRMD Position: Q3 2023 in Review

Nebula Research & Development sold out of CorMedix (CRMD) in Q3 2023, closing a stake of 14,475 shares — an estimated $57.4K sold.

Nebula Research & Development first reported a position in CRMD in Q2 2023 and held it in 1 quarter. The position peaked at $57.4K in Q2 2023. 92 funds tracked by Wall St. Rank hold CRMD as of Q3 2023.

  • Nebula Research & Development reported no remaining CorMedix position as of Q3 2023 after selling out during the quarter.
  • Nebula Research & Development sold 14,475 CorMedix shares in Q3 2023, an estimated $57.4K.
  • Nebula Research & Development first reported a position in CorMedix in Q2 2023 and held it in 1 quarter.
  • Nebula Research & Development's CorMedix position peaked at $57.4K in Q2 2023.
  • 92 funds tracked by Wall St. Rank held CorMedix as of Q3 2023.

Based on Nebula Research & Development's 13F filing for Q3 2023, filed 14 Nov 2023.